NVS starts phase-3 trial of Enbrel FoB: http://in.reuters.com/article/2013/06/24/us-novartis-enbrel-idINBRE95N05Y20130624 Given the IP protection for Enbrel in the US, which runs until 2028 (#msg-69263618), NVS’ FoB is presumably intended for ex-US markets only.